News Biotest AG

Equities

BIO3

DE0005227235

Market Closed - Xetra Other stock markets 11:36:02 2024-05-06 am EDT			5-day change	1st Jan Change
28 ^EUR	-2.10%		-2.44%	-9.68%

Apr. 19	Biotest Launches New Plasma Collection Center in Germany	MT
Mar. 28	Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biotest Launches New Plasma Collection Center in Germany	Apr. 19	MT
Biotest AG opens 12th plasma collection centre in Germany	Apr. 19	EQ
Biotest AG increased sales by 32% in the financial year 2023	Mar. 28	EQ
Biotest : Sustainability report Declaration of compliance 2023	Mar. 28	PU
Biotest Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Biotest : Invitation / Agenda of Annual General Meeting 2024	Mar. 25	PU
Biotest : Notes on agenda item 1 - German Version	Mar. 24	PU
Biotest achieves EBIT forecast for 2023	Feb. 29	EQ
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care	Feb. 28	EQ
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate	Feb. 14	EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	Jan. 30	EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	Jan. 22	EQ
Biotest AG opens 11th plasma collection centre in Germany	Jan. 18	EQ
AFR: Biotest AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	Jan. 11	EQ
Biotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP)	Dec. 12	EQ
Biotest’s Trimodulin shows reduced mortality in patients with severe community-acquired pneumonia through rapid normalisation of inflammation	Nov. 28	EQ
Biotest Aktiengesellschaft Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023	Nov. 02	EQ
Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024	23-10-05	CI
Biotest AG: Increase of the EBIT guidance	23-10-05	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biotest AG

Equities

BIO3

DE0005227235

Summary

Filters